Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRV NASDAQ:DERM NASDAQ:KYTX NASDAQ:PBYI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRVAcrivon Therapeutics$1.43+2.9%$1.25$1.05▼$10.16$44.84M1.64355,259 shs331,394 shsDERMJourney Medical$7.59-1.0%$7.13$3.54▼$8.25$176.82M0.8193,787 shs89,000 shsKYTXKyverna Therapeutics$4.33+2.1%$3.17$1.78▼$10.08$187.14M2.95596,523 shs125,786 shsPBYIPuma Biotechnology$3.28-3.5%$3.44$2.22▼$4.13$162.79M1.29336,143 shs300,286 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRVAcrivon Therapeutics+2.88%+5.93%+7.52%-12.80%-82.13%DERMJourney Medical-1.04%+5.56%+8.90%+1.61%+40.56%KYTXKyverna Therapeutics+2.12%+11.03%+41.04%+106.19%-51.46%PBYIPuma Biotechnology-3.53%-3.53%-0.91%+9.33%-12.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRVAcrivon Therapeutics3.699 of 5 stars3.55.00.00.02.73.30.6DERMJourney Medical2.3218 of 5 stars3.51.00.00.03.31.70.6KYTXKyverna Therapeutics2.7026 of 5 stars3.62.00.00.03.31.70.6PBYIPuma Biotechnology4.2332 of 5 stars3.52.00.00.02.64.23.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRVAcrivon Therapeutics 3.00Buy$17.711,138.76% UpsideDERMJourney Medical 3.00Buy$9.5025.16% UpsideKYTXKyverna Therapeutics 3.14Buy$18.50327.25% UpsidePBYIPuma Biotechnology 3.00Buy$7.00113.41% UpsideCurrent Analyst Ratings BreakdownLatest ACRV, PBYI, KYTX, and DERM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025KYTXKyverna TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00 ➝ $5.005/16/2025ACRVAcrivon TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/15/2025DERMJourney MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/15/2025ACRVAcrivon TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.005/5/2025ACRVAcrivon TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$6.005/4/2025ACRVAcrivon TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRVAcrivon TherapeuticsN/AN/AN/AN/A$5.68 per shareN/ADERMJourney Medical$56.13M3.15N/AN/A$0.91 per share8.34KYTXKyverna Therapeutics$7.03M26.62N/AN/A$6.17 per share0.70PBYIPuma Biotechnology$230.50M0.71$0.85 per share3.85$1.88 per share1.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRVAcrivon Therapeutics-$80.56M-$2.220.00N/AN/AN/A-44.66%-40.94%8/12/2025 (Estimated)DERMJourney Medical-$14.67M-$0.390.00N/AN/A-14.76%-52.03%-11.28%8/11/2025 (Estimated)KYTXKyverna Therapeutics-$127.48M-$3.380.00N/AN/AN/A-51.66%-45.92%8/11/2025 (Estimated)PBYIPuma Biotechnology$30.28M$0.774.268.63N/A16.37%49.35%18.25%7/30/2025 (Estimated)Latest ACRV, PBYI, KYTX, and DERM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ACRVAcrivon Therapeutics-$0.57N/AN/AN/AN/AN/A8/11/2025Q2 2025DERMJourney Medical-$0.06N/AN/AN/A$14.93 millionN/A8/11/2025Q2 2025KYTXKyverna Therapeutics-$1.00N/AN/AN/AN/AN/A8/7/2025Q2 2025PBYIPuma Biotechnology$0.11N/AN/AN/A$52.00 millionN/A5/14/2025Q1 2025DERMJourney Medical-$0.24-$0.18+$0.06-$0.18$12.05 million$13.14 million5/13/2025Q1 2025ACRVAcrivon Therapeutics-$0.57-$0.51+$0.06-$0.51N/AN/A5/13/2025Q1 2025KYTXKyverna Therapeutics-$1.21-$1.03+$0.18-$1.03N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRVAcrivon TherapeuticsN/AN/AN/AN/AN/ADERMJourney MedicalN/AN/AN/AN/AN/AKYTXKyverna TherapeuticsN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRVAcrivon TherapeuticsN/A11.1711.17DERMJourney Medical1.071.341.03KYTXKyverna TherapeuticsN/A7.447.44PBYIPuma Biotechnology0.111.531.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRVAcrivon Therapeutics71.62%DERMJourney Medical7.25%KYTXKyverna Therapeutics18.08%PBYIPuma Biotechnology61.29%Insider OwnershipCompanyInsider OwnershipACRVAcrivon Therapeutics11.90%DERMJourney Medical15.03%KYTXKyverna Therapeutics22.00%PBYIPuma Biotechnology23.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRVAcrivon Therapeutics5831.35 million27.62 millionNot OptionableDERMJourney Medical9023.30 million19.80 millionN/AKYTXKyverna Therapeutics9643.22 million33.71 millionOptionablePBYIPuma Biotechnology20049.63 million38.07 millionOptionableACRV, PBYI, KYTX, and DERM HeadlinesRecent News About These CompaniesPuma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial ResultsJuly 24 at 4:15 PM | businesswire.comAlessandra Cesano Sells 27,000 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) StockJuly 23 at 9:18 PM | marketbeat.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells $90,990.00 in StockJuly 23 at 5:36 AM | insidertrades.comAdd These 4 Top-Ranked Liquid Stocks to Boost Portfolio ReturnsJuly 15, 2025 | zacks.comPuma Biotechnology (NASDAQ:PBYI) Share Price Passes Above 200-Day Moving Average - Here's WhyJuly 15, 2025 | marketbeat.comAre Investors Undervaluing Puma Biotechnology (PBYI) Right Now?July 14, 2025 | zacks.comWhy Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for ... - NasdaqJuly 12, 2025 | nasdaq.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Insider Sells $12,188.22 in StockJuly 11, 2025 | insidertrades.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Insider Sells $12,188.22 in StockJuly 10, 2025 | marketbeat.comInsider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) Insider Sells 4,374 Shares of StockJuly 10, 2025 | marketbeat.comInsider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) CEO Sells 21,580 Shares of StockJuly 10, 2025 | marketbeat.comPuma Biotechnology, Inc. (NASDAQ:PBYI) CEO Alan H. Auerbach Sells 25,592 SharesJuly 10, 2025 | marketbeat.comWhy Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value InvestorsJuly 10, 2025 | zacks.comPuma Biotechnology (NASDAQ:PBYI) Stock Crosses Above 200 Day Moving Average - Should You Sell?July 5, 2025 | marketbeat.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)July 2, 2025 | businesswire.comIs Puma Biotechnology (PBYI) Stock Undervalued Right Now?June 27, 2025 | zacks.comFast-paced Momentum Stock Puma Biotech (PBYI) Is Still Trading at a Bargain - NasdaqJune 26, 2025 | nasdaq.comPuma Biotechnology: Updated Timelines And A Resurgence In SentimentJune 25, 2025 | seekingalpha.comFast-paced Momentum Stock Puma Biotech (PBYI) Is Still Trading at a BargainJune 24, 2025 | zacks.comInsider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells 8,100 Shares of StockJune 18, 2025 | insidertrades.comShould Value Investors Buy Puma Biotechnology (PBYI) Stock?June 11, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACRV, PBYI, KYTX, and DERM Company DescriptionsAcrivon Therapeutics NASDAQ:ACRV$1.43 +0.04 (+2.88%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.42 -0.01 (-1.05%) As of 07/25/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.Journey Medical NASDAQ:DERM$7.59 -0.08 (-1.04%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$7.59 0.00 (0.00%) As of 07/25/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.Kyverna Therapeutics NASDAQ:KYTX$4.33 +0.09 (+2.12%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$4.33 0.00 (0.00%) As of 07/25/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.Puma Biotechnology NASDAQ:PBYI$3.28 -0.12 (-3.53%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$3.27 -0.01 (-0.30%) As of 07/25/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.